Trial Profile
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Meropenem/vaborbactam (Primary) ; Antibacterials
- Indications Bacteraemia; Enterobacteriaceae infections; Intra-abdominal infections; Pyelonephritis; Urinary tract infections; Ventilator associated pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms TANGO 2; TANGO II
- Sponsors Rempex Pharmaceuticals; The Medicines Company
- 07 Jun 2021 Results of a population pharmacokinetic analysis using pooled data from two Phase 1 (Rempex501 & Rempex504) and two Phase 3 studies ( TANGO 1 & TANGO 2) published in the Antimicrobial Agents and Chemotherapy
- 19 Nov 2020 Results evaluating cost-effectiveness of Vaborem in the Italian setting, by taking data efficacay data from TANGO II, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 16 May 2019 Results of Post Hoc analysis assessing the efficacy of MV versus best available therapy in the subgroup of patients without prior antimicrobial failure published in the Advances in Therapy.